GENERAL COMMENTS
The protocol addresses an important issue that could have a great impact in acute urticaria ER management. Moreover, it is one of the more frequent causes to attend the ER Department. It is very well designed; the aimed sample is large enough to raise sound conclusions.
I have some suggestions that could improve the study:
1.
Remove inducible urticarias as an inclusion criteria. Inducible urticarias are by definition chronic, and if included will alter the results; Moreover, all inducible urticarias but delayed pressure and vibratory urticaria/angioedema do respond to antihistamines and do not improve utilizing corticosteroids. 2.
In order to be more conservative, I would include patients with first isolated acute urticaria episode since those patients with previous acute urticaria episodes could be affected form other types of urticaria. 3.
Please clarify if the primary outcome is UAS7, which is the aggregate of 7 days UAS. 4.
The number of hives mentioned in the protocol (page 9 lines 44-47) does not agree with the UAS score, please be accurate otherwise the data would not be valid. Please clarify how acute urticaria due to allergens or drug allergy will be ruled out. 7.
Please specify for how long the patients will stay in observation admitted at ER 8.
The authors should highlight two outcomes of the study that could merge from this study: a.
The utilization of the oral route b.
The utilization of second generation of antihistamines The majority of patients that attend an ER Department receive parenteral first-generation antihistamines. Once they get admitted in the ER a line is placed and there is just one antihistamine available by iv route. 9.
In the rationale of the study, it would be worth to mention the mechanisms of corticoids action, with days, they reduce mast cell number but do not inhibit mast cell degranulation (Ref. 
The manuscript "Corticosteroids for acute urticarial: study protocol for a double-blind non-inferiority randomized controlled trial" should be of interest to readers of BMJopen. After my experience, non-inferiority trials could be used more in clinical research. New treatments might not always be better on the primary endpoint, but be cheaper and with fewer side-effects. I have primarily assessed the statistical methods. The sample size calculation seems appropriate. I recommend the authors to write a statistical analysis plan before they conduct the statistical calculations. Shaprio-Wilk and other statistical tests for non-normality get increased power with larger sample size. On the other hand, parametric tests as independent samples t-tests get more robust from non-normality with increased sample size (cfr. central limit theorem). They might assess the normality assumptions with descriptive methods in addition to statistical tests for normality before they make a decision. This can be outlined in the statistical analysis plan.
VERSION 1 -AUTHOR RESPONSE
Reviewer ( This protocol addresses the treatment of acute urticaria, and the treatment will be for the first 14 days which is in line with the definition of acute urticaria. However it remains unclear what will happen with patients after these 14 days. The definition of chronic urticaria is that it persists for more than 6 weeks and for chronic urticaria the treatment with glucocorticoids is not encouraged by guidelines. In this study however patients will be observed up to 6 months. What happens with patients who will suffer finally from a chronic spontaneous urticaria? Precision was made in Methods/Design, Interventions section: "After D14, the choice of 2nd generation H1-antihistamines fourfold dose or adjunctive medication (omalizumab, ciclosporin A) administered to support 1st step treatment was left to the discretion of the treating dermatologist physician. Glucocorticoids are not allowed. "
Minor point: the correct pharmacological term for steroids with antiinflammatory activity like prednisone is glucocorticoid and not corticosteroid. Corrections were made throughout the text. Glucocorticoid replaced corticosteroid. In order to be more conservative, I would include patients with first isolated acute urticaria episode since those patients with previous acute urticaria episodes could be affected form other types of urticaria. We wish to include all acute urticaria that represent a real-life clinical setting in emergency departments. Other urticaria, especially chronic urticaria, will not be included since the exclusion criteria protect from the inclusion of patients who have taken corticosteroids, antihistamines at an already higher dose than the baseline, and patients who are already on treatment for chronic urticaria. 3.
Please clarify if the primary outcome is UAS7, which is the aggregate of 7 days UAS. Clarification was made in Methods/Design, Trial outcomes section: "Primary outcome is UAS7". 4.
The number of hives mentioned in the protocol (page 9 lines 44-47) does not agree with the UAS score, please be accurate otherwise the data would not be valid. Please specify if it is available the UAS7 score validated in French. Precision was made. in the Methods/Design, Trial outcomes section: "UAS7, which is validated in French." 6.
Please clarify how acute urticaria due to allergens or drug allergy will be ruled out. For isolated acute hives due to allergens or drug allergy without anaphylaxis manisfestations, the same treatment (ie: antihistamines and/or glucocorticoids) will be administrated as others acute urticaria forms. 7.
Please specify for how long the patients will stay in observation admitted at ER Precision was made. in the Methods/Design, Intervention section: "In both groups, patients stay minimally one hour in emergency department." 8.
The utilization of second generation of antihistamines The majority of patients that attend an ER Department receive parenteral first-generation antihistamines. Once they get admitted in the ER a line is placed and there is just one antihistamine available by iv route. Highlight was made in Discussion section: "this study could show the interest of using the oral route and second-generation of antihistamines in patients with acute urticaria while they often receive a first-generation antihistamine intravenously in emergency departments".
9.
In the rationale of the study, it would be worth to mention the mechanisms of corticoids action, with days, they reduce mast cell number but do not inhibit mast cell degranulation (Ref. Cole ZA, Clough GF, Church MK. Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo. Br J Pharmacol. 2001 Jan; 132(1):286-92 Precision was made in Introduction section: "Indeed, with days, glucocorticoids reduce mast cell number but do not inhibit mast cell degranulation". Reference was added in REFERENCES section. 10. Please include the limitations of the study Limitation was added in the Discussion section: "Main limitation of our trial should be noted. Our results do apply to selected patients and cannot be generalized to all patients with acute urticaria. Patients with anaphylaxis and angioedema without urticaria which is more often mast-cell mediated are not included in this study." The manuscript "Corticosteroids for acute urticarial: study protocol for a double-blind non-inferiority randomized controlled trial" should be of interest to readers of BMJ open. After my experience, noninferiority trials could be used more in clinical research. New treatments might not always be better on the primary endpoint, but be cheaper and with fewer side-effects. I have primarily assessed the statistical methods. The sample size calculation seems appropriate. I recommend the authors to write a statistical analysis plan before they conduct the statistical calculations. Shaprio-Wilk and other statistical tests for non-normality get increased power with larger sample size. On the other hand, parametric tests as independent samples t-tests get more robust from non-normality with increased sample size (cfr. central limit theorem). They might assess the normality assumptions with descriptive methods in addition to statistical tests for normality before they make a decision. This can be outlined in the statistical analysis plan. We thank the reviewer for his useful comments: As suggested we mentioned in the revised version that in addition to statistical tests normality will be assessed by graphical methods and we also mentioned that a statistical analysis plan describing in details all the statistical procedures will be written before database freezing.
